Evidence map›Paper›PMID 39730334›Full record

ArticleNature communications2024

Structural and functional determination of peptide versus small molecule ligand binding at the apelin receptor.

Thomas L Williams, Grégory Verdon, Rhoda E Kuc, Heather Currinn, Brian Bender, Nicolae Solcan, Oliver Schlenker, Robyn G C Macrae, Jason Brown, Marco Schütz and 7 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Structure of the GNature communications · 2025
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Thomas L Williams *Experimental Medicine & Immunotherapeutics, University of Cambridge, Cambridge, UK.ORCID 0000-0002-1051-0595
Grégory Verdon *Nxera Pharma UK Limited (Sosei Heptares), Steinmetz Building, Granta Park, Cambridge, UK.
Rhoda E KucExperimental Medicine & Immunotherapeutics, University of Cambridge, Cambridge, UK.
Heather CurrinnNxera Pharma UK Limited (Sosei Heptares), Steinmetz Building, Granta Park, Cambridge, UK.
Brian BenderNxera Pharma UK Limited (Sosei Heptares), Steinmetz Building, Granta Park, Cambridge, UK.
Nicolae SolcanNxera Pharma UK Limited (Sosei Heptares), Steinmetz Building, Granta Park, Cambridge, UK.
Oliver SchlenkerNxera Pharma UK Limited (Sosei Heptares), Steinmetz Building, Granta Park, Cambridge, UK.
Robyn G C MacraeExperimental Medicine & Immunotherapeutics, University of Cambridge, Cambridge, UK.
Jason BrownNxera Pharma UK Limited (Sosei Heptares), Steinmetz Building, Granta Park, Cambridge, UK.
Marco SchützNxera Pharma UK Limited (Sosei Heptares), Steinmetz Building, Granta Park, Cambridge, UK.
Andrei ZhukovNxera Pharma UK Limited (Sosei Heptares), Steinmetz Building, Granta Park, Cambridge, UK.
Sanjay SinhaWellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK.ORCID 0000-0001-5900-1209
Chris de GraafNxera Pharma UK Limited (Sosei Heptares), Steinmetz Building, Granta Park, Cambridge, UK.
Stefan GräfNIHR BioResource for Translational Research - Rare Diseases, Cambridge Biomedical Campus, Cambridge, UK.ORCID 0000-0002-1315-8873
Janet J MaguireExperimental Medicine & Immunotherapeutics, University of Cambridge, Cambridge, UK.ORCID 0000-0002-9254-7040
Alastair J H BrownNxera Pharma UK Limited (Sosei Heptares), Steinmetz Building, Granta Park, Cambridge, UK. Alastair.Brown@Nxera.life.
Anthony P DavenportExperimental Medicine & Immunotherapeutics, University of Cambridge, Cambridge, UK. apd10@medschl.cam.ac.uk.ORCID 0000-0002-2096-3117

Funding

British Heart Foundation (BHF) FS/17/61/33473British Heart Foundation (BHF) FS/18/46/33663British Heart Foundation (BHF) TG/18/4/33770Medical Research Council MC_PC_17230Wellcome TrustWellcome Trust (Wellcome) 203814/Z/16/A
6 · The paper itself

Abstract

We describe a structural and functional study of the G protein-coupled apelin receptor, which binds two endogenous peptide ligands, apelin and Elabela/Toddler (ELA), to regulate cardiovascular development and function. Characterisation of naturally occurring apelin receptor variants from the UK Genomics England 100,000 Genomes Project, and AlphaFold2 modelling, identifies T89

Indexed as

ApelinApelin ReceptorsProtein BindingBinding SitesCrystallography, X-RayHEK293 CellsHumansLigandsModels, MolecularMyocytes, CardiacPeptide HormonesPeptidesAPELA protein, humanApelinApelin ReceptorsAPLNR protein, humanLigandsPeptide HormonesPeptides

Identifiers

PMID39730334
PMCPMC11680790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.